Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Metropolis Healthcare Ltd.
Source DateBoard Meeting DateDetails
05-May-2025 13-May-2025 Audited Results
29-Jan-2025 04-Feb-2025 Quarterly Results
05-Dec-2024 09-Dec-2024 Preferential Issue of shares Inter-alia to consider and approve the following: 1. Issuance of equity shares of the Company on a preferential basis, in accordance with the applicable laws, subject to the approval of shareholders of the Company and such other statutory approvals, as may be required. 2. Postal ballot notice for seeking shareholders approval in respect of the aforesaid proposal, if approved by the Board.
30-Oct-2024 08-Nov-2024 Quarterly Results
05-Aug-2024 10-Aug-2024 Quarterly Results
14-May-2024 21-May-2024 Audited Results
29-Jan-2024 02-Feb-2024 Quarterly Results
30-Oct-2023 04-Nov-2023 Quarterly Results & Interim Dividend
27-Jul-2023 02-Aug-2023 Quarterly Results
17-May-2023 16-May-2023 Audited Results(Cancelled)
10-May-2023 16-May-2023 Audited Results
06-Feb-2023 10-Feb-2023 Quarterly Results & Interim Dividend
31-Oct-2022 08-Nov-2022 Quarterly Results
04-Aug-2022 10-Aug-2022 Quarterly Results
12-Jul-2022 18-Jul-2022 Inter alia, to consider and approve the revised Audited Standalone Financial results of the Company for the Quarter and Year ended March 31,2022 after taking on record the amalgamation of the 8(Eight) wholly owned Subsidiary Companies with the Company.
16-May-2022 24-May-2022 Audited Results
03-Feb-2022 11-Feb-2022 Quarterly Results & Interim Dividend
03-Nov-2021 10-Nov-2021 Quarterly Results
02-Aug-2021 06-Aug-2021 Quarterly Results & Inter alia, to consider and approve Proposal for raising funds either by way of private placement or preferential issue or public issue or through any other permissible mode and/or combination thereof, including by way of Qualified Institutions Placement, in accordance with applicable laws; and other matters
21-May-2021 27-May-2021 Audited Results
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.